If you are not measuring muscle during a GLP-1 course, you are flying blind on the variable that matters most
Informal reports sometimes describe body-composition changes after 4 to 6 weeks, while animal studies measured changes over 11 to 28 days
Looks so natural - they clearly know what they're doing
Likewise, individuals undergoing immunosuppressive treatment warrant careful assessment due to potential modulation of immune system activity and tissue repair mechanisms
treatment should be discontinued if pancreatitis is suspected Gallbladder disease including cholelithiasis and cholecystitis has been reported, particularly with weight loss Dehydration and acute kidney injury risk, especially during treatment initiation Diabetic retinopathy complications have been associated with rapid glucose improvement (particularly with semaglutide) [23] [24] Hypoglycaemia risk when combined with insulin or sulphonylureas According to UK product information, GLP-1 receptor agonists are not recommended during pregnancy or breastfeeding when used for weight management
Now researchers are studying them for a surprising range of health conditionsand the findings go well beyond managing type 2 diabetes and obesity